Inactive Instrument

PCAS Stock

PCA

FR0000053514

News in other languages : PCAS

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
18/12/23	PCAS : augmentation de capital de 200 ME

More news

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
18/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
24/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
16/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

24/10/23	PCAS: Net Sales as of September 30, 2023	GL
06/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
27/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
02/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	-1.12%	-5.49%	+60.19%	+112.43%	1,048B
JOHNSON & JOHNSON	-1.57%	-0.60%	+50.33%	+59.86%	640B
ABBVIE INC.	-1.81%	-1.41%	+24.07%	+75.98%	456B
ROCHE HOLDING AG	-0.51%	-3.65%	+38.66%	+39.65%	362B
NOVARTIS AG	+0.09%	-2.09%	+22.87%	+37.92%	295B
ASTRAZENECA PLC	0.00%	+0.51%	+2.02%	+12.11%	255B
AMGEN INC.	-0.76%	+0.75%	+51.75%	+70.45%	236B
NOVO NORDISK A/S	+0.69%	-1.25%	-17.20%	-54.04%	204B
GILEAD SCIENCES, INC.	+0.52%	+3.78%	+30.67%	+93.68%	185B
Average	+0.16%	-0.72%	+29.26%	+49.78%	409.07B
Weighted average by Cap.	+0.33%	-1.92%	+38.56%	+65.85%

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news : PCAS

Press Releases : PCAS

News in other languages : PCAS

Managers and Directors : PCAS

Other Pharmaceuticals

Company Profile